新型冠状病毒感染合并真菌感染患者的临床特征分析

Differences in clinical characteristics among patients with corona virus disease 2019 combined with fungal infections

目的 探讨新型冠状病毒感染(COVID-19)合并真菌感染患者的临床特征。方法 选取2022年9月至2023年9月深圳市第二人民医院收治的COVID-19合并真菌感染患者,分析不同真菌感染患者的临床特征,对有统计学差异的临床特征进行组间比较。结果 共纳入196例患者,分别合并念珠菌、曲霉菌、毛霉菌及混合真菌感染。混合真菌感染组相较于念珠菌组、曲霉菌组及毛霉菌组,患者死亡率升高、免疫功能差、真菌药物联合使用率高,真菌治疗时间延长,真菌药物治疗费用增多(均P<0.05);曲霉菌组和毛霉菌组相较于念珠菌组的真菌治疗时间延长,真菌药物治疗费用增多(均P<0.05)。结论 COVID-19合并不同真菌感染患者临床特征存在差异,临床应重点关注COVID-19合并混合真菌感染患者。

Objective To analyze the differences in clinical characteristics among patients with corona virus disease 2019(COVID-19)combined with fungal infections.Methods Patients with COVID-19 combined with fungal infections admitted to Shenzhen Second People's Hospital from September 2022 to September 2023 were included.The differences in clinical characteristics among patients with different fungal infections were analyzed,and comparisons of clinical characteristics with statistical differences between the groups were conducted.Results A total of 196 patients were enrolled,with infections involving candida spp.,aspergillus spp.,mucor spp.,and mixed fungal infections.Compared to the candida spp.,aspergillus spp.,and mucor spp.groups,the mixed fungal infection group showed higher mortality rates,poorer immune status,higher rates of combined antifungal drug use,longer durations of antifungal treatment,and increased costs of antifungal treatment(P<0.05).Additionally,both the aspergillus spp.and mucor spp.groups showed longer durations of antifungal treatment and higher costs of antifungal treatment compared to the candida spp.groups(P<0.05).Conclusion Clinical characteristics differ among patients with COVID-19 combined with different fungal infections,and particular attention should be given to patients with COVID-19 combined with mixed fungal infections.